Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$17,500.00
Modifications to a hybrid ß-hexosaminidase for transcytosis across the blood-brain barrier
FY 2018-19
Summary
Tay-Sachs disease and Sandhoff disease are severe neurodegenerative diseases caused by the heritable loss of lysosomal beta-hexosaminidase A (Hex A) activity. In severe cases, neurological symptoms occur by 6-12 months of age, followed by rapid decline and death by 1-4 years of age; whereas, in cases where mutations result in residual HexA activity, GM2-ganglioside accumulation is slowed, and disease onset occurs during adolescence or early adulthood. There are no treatments available for patients affected by these diseases.
Lysosomal HexA is responsible for the breakdown of GM2 ganglioside, which is a component of the neuronal plasma membrane that is constantly recycled by the cell. When there are insufficient levels of HexA, GM2 ganglioside accumulate to pathological levels in neurons of the central and peripheral nervous system. Only ~10% of normal HexA activity is needed to prevent, and possibly reverse GM2 ganglioside accumulation, making enzyme replacement therapy (ERT) a promising approach to manage Tay-Sachs and Sandhoff disease. To enable the approach, we recently engineered a stable form of Hex (known as HexM) that has addressed issues of HexA instability and production, and it degrades GM2 ganglioside both in cellulo and in vivo. However, intravenously administered HexM must be able to cross the blood brain barrier (BBB) to affect GM2 degradation in the central nervous system. To address this, I aim to fuse HexM to the receptor binding domains of Apolipoproteins B and E to ‘trick’ the BBB into transporting the enzyme into the CNS, which will be tested using an in vitro BBB model. I have already developed a robust overexpression system for ‘wild-type’ HexM and will employ the same approach to generate the HexM fusion in quantities sufficient for ERT studies.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
419433
Name
Bouma Kristen A
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Modifications to a hybrid ß-hexosaminidase for transcytosis across the blood-brain barrier
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Apolipoprotein; Blood-Brain Barrier; Enzyme Replacement Therapy; Gm2 Gangliosidosis; Hexm; Lysosomal Storage Disorder; Sandhoff Diseas; Ss-Hexosaminidase; Tay-Sachs Disease
Abstract
Tay-Sachs disease and Sandhoff disease are severe neurodegenerative diseases caused by the heritable loss of lysosomal beta-hexosaminidase A (Hex A) activity. In severe cases, neurological symptoms occur by 6-12 months of age, followed by rapid decline and death by 1-4 years of age; whereas, in cases where mutations result in residual HexA activity, GM2-ganglioside accumulation is slowed, and disease onset occurs during adolescence or early adulthood. There are no treatments available for patients affected by these diseases.
Lysosomal HexA is responsible for the breakdown of GM2 ganglioside, which is a component of the neuronal plasma membrane that is constantly recycled by the cell. When there are insufficient levels of HexA, GM2 ganglioside accumulate to pathological levels in neurons of the central and peripheral nervous system. Only ~10% of normal HexA activity is needed to prevent, and possibly reverse GM2 ganglioside accumulation, making enzyme replacement therapy (ERT) a promising approach to manage Tay-Sachs and Sandhoff disease. To enable the approach, we recently engineered a stable form of Hex (known as HexM) that has addressed issues of HexA instability and production, and it degrades GM2 ganglioside both in cellulo and in vivo. However, intravenously administered HexM must be able to cross the blood brain barrier (BBB) to affect GM2 degradation in the central nervous system. To address this, I aim to fuse HexM to the receptor binding domains of Apolipoproteins B and E to ‘trick’ the BBB into transporting the enzyme into the CNS, which will be tested using an in vitro BBB model. I have already developed a robust overexpression system for ‘wild-type’ HexM and will employ the same approach to generate the HexM fusion in quantities sufficient for ERT studies.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bouma, Kristen A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~